Filatova E S, Turovskaya E F, Alekseeva L I
V.A. Nasonova Research Institute of Rheumatology, Russian Academy of Sciences, Moscow, Russia.
Ter Arkh. 2017;89(12):81-85. doi: 10.17116/terarkh2017891281-85.
To evaluate the efficacy of pregabalin in the therapy of chronic pain in patients with knee osteoarthritis (KOA).
The study enrolled 60 patients with KOA and neuropathic pain component (NPC) (Douleur Neuropathique en 4 questions (DN4) questionnaire scores, >4) who were randomized into two groups to receive aceclofenac or aceclofenac + pregabalin for 5 weeks. All the patients underwent clinical and neurological examinations, assessment of the functional WOMAC index, pain intensity at rest and during movement, and diagnosis of neuropathic pain (NP) (DN4 and Pain DETECT questionnaires).
Both groups were observed to have positive changes in the studied parameters; however, combination therapy using an anticonvulsant drug (pregabalin) showed a more pronounced positive effect against not only NPC, but also the functional activity (WOMAC) and severity of pain (visual analogue scale).
Combination therapy using pregabalin in KOA patients having the signs of NP is more effective than monotherapy with nonsteroidal anti-inflammatory drugs (aceclofenac).
评估普瑞巴林治疗膝关节骨关节炎(KOA)患者慢性疼痛的疗效。
本研究纳入60例伴有神经病理性疼痛成分(NPC)(神经病理性疼痛4项问卷(DN4)评分>4)的KOA患者,将其随机分为两组,分别接受醋氯芬酸或醋氯芬酸+普瑞巴林治疗5周。所有患者均接受临床和神经学检查、功能WOMAC指数评估、静息和运动时的疼痛强度评估以及神经病理性疼痛(NP)诊断(DN4和疼痛检测问卷)。
两组研究参数均有积极变化;然而,使用抗惊厥药物(普瑞巴林)的联合治疗不仅对NPC,而且对功能活动(WOMAC)和疼痛严重程度(视觉模拟量表)均显示出更显著的积极效果。
在有NP体征的KOA患者中,使用普瑞巴林的联合治疗比使用非甾体抗炎药(醋氯芬酸)的单一治疗更有效。